Intermittent Endocrine Treatment of Prostate Cancer

Czech version

Authors: V. Vachalovský; J. Dvořáček
Authors‘ workplace: Urologická klinika 1. LF UK a VFN, Praha
Published in: Čas. Lék. čes. 2002; : 669-672
Category:

Overview

Intermittent endocrine treatment or cyclic therapy of prostate cancer aims at prolonging survival by delayingprogression to androgene independence and at improving quality of life by avoiding the side effects of continuousandrogen ablation. Intermittent endocrine treatment is capable of inducing multiple apoptoic regressions and ofimprovement in quality of life including sexual functions. The recommended lenght of therapeutic period is 6–9months. The mean off-therapy interval approaches 50 % of the duration of the treatment cycle. The mean time todisease progression is 32 month. The definitive answer to the question of prolonged survival awaits the completionof ongoing randomized studies.

Key words:
prostate cancer, intermittent androgen treatment.

Full text is not available online.

If interested in a scan of this journal, contact NTO ČLS JEP.

Labels

Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management

A Deadly Pandemic is SpreadingThe Devastating Impact of Smoking is a Serious Warning for All

Contemporary Possibilities of Vascular Surgery

Effects of Non-Steroidal Anti-Inflammatory Drugs to the GastrointestinalTract

Phone Survey of the Home Prostitution

Statistical Method for Long-term Follow up the Death Rate of Selected Causes

Article was published in

Journal of Czech Physicians

2002 Issue 21

Download issue PDF